StemCell Therapy

BEIJING--(BUSINESS WIRE)--

The Prostate Cancer Foundation today announced its first two Young Investigators in China to launch its initiative to identify, fund and promote innovative research projects within China. As with all of its funded research across the globe, the PCF China program carries the ultimate goal of ending death and suffering from prostate cancer.

PCFs first two Young Investigators in China will be honored at a special awards dinner this evening following PCF Chinas First Annual Prostate Cancer Symposium being held today at Peking Universitys Wu Jieping Urology Center, 9:0015:00. The awards ceremony will be held at the Four Points Hotel by Sheraton, Tower 1, 25 Yuanda Road, Haidian District, Beijing, 18:00-21:00.

The 2012 PCF China Young Investigator Award recipients are sponsored anonymously by a long-time PCF donor and are:

Shancheng Ren, MD, PhD Shanghai Changhai Hospital Mentor: Yinghao Sun, MD, PhD

Gene fusions are the erroneous juxtaposition of two genes that do not normally lie next to each other on the genome. As a result of this abnormal placement of two genes, their expression is altered and this may lead to the development and progression of cancer. The TMPRSS2-ERG gene fusions are a hallmark of prostate cancer (PCa), found in ~50% of Caucasian patients. Recent studies have shown that these TMPRSS2-ERG gene fusions occur at a much lower frequency of ~15-20% in prostate cancer patients in China. The underlying genetic heterogeneity/differences among different ethnic populations may explain this observation.

Dr. Shancheng Ren has identified a novel gene fusion in prostate cancer patients in China that results in the juxtaposition of the SDK1 and the AMACR genes. Dr. Ren proposes to study the relative prevalence and clinical significance of this SDK1-AMACR gene fusion in Chinese PCa patients. Dr. Ren also proposes to investigate the SDK1-AMACR gene fusion as a novel, non-invasive marker for the detection of prostate cancer in Chinese patients.

Dr. Ren and team recently published a paper in Cell Research, describing the role of specific gene fusions in Chinese patients. Read the published paper.

Yuxi Zhang, MD, PhD The First Hospital of China Medical University Mentor: Chuize Kong, MD, PhD

Male hormones (androgens) fuel prostate cancer progression and the first line of treatment is Androgen Deprivation Therapy (ADT). Unfortunately, most prostate cancer patients ultimately become resistant to ADT. This stage of prostate cancer is termed castration-resistant prostate cancer (CRPC) and heralds metastasis and an increased risk for death. Researchers recently identified prostate cancer-specific stem cells (PrCSC) that are proposed to play a major role in the development of treatment resistance and progression of prostate cancer. Studies of PrCSCs have shown that these cells are capable of self-renewal, possess enhanced tumor-initiating capabilities, do not rely on androgens for growth and survival and are therefore more resistant to treatment than other cancerous cells. In a previous study, Dr. Zhang has identified a sub-population of PrCSCs that increase in numbers upon treatment with ADT. He observed that this specific sub-population of stem cells decreased when the castration-resistant tumors were treated with androgens and a different PrCSC subset became more prominent in the tumors.

More:
The Prostate Cancer Foundation Expands Global Reach, Adds First Two PCF Young Investigators in China

This entry was posted on March 10, 2012 at 6:23 am and is filed under Death by Stem Cells. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |